Journal Club

Kestrel's $1.45 billion AbbVie Deal, FDA Approves First Ever PROTAC, and Werewolf Breaks Arsenal Lease.

Plus more details on Windgap's big pharma partnership and a number of people moves.

C4's Partnership with Roche, Gilead Options Kymera degrader, and Astellas Licenses Dyno Capsid.

Plus the initial dosing of Enanta and Avencell's Clinical Trials

Watertown Bio Journal Club - Improving Vaccine Immunogenicity with Corner Therapeutics

the very model of a modern adjuvant general

Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation

Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates

Watertown Journal Club - Exploring the oRNA behind ORNA Therapeutics

Watertown Bio Journal Club: How Targeted is Targeted Protein Degradation?

Evaluating the potential impact of off-target degradation of KT-474

Watertown Bio Journal Club: Engineering Plastic Eating- and Concrete Laying Bacteria

Plus, How to design a PROTAC

Watertown Bio Journal Club - How Many Ways Can You Break a Protein?

Talking about proteases, PROTACs, and molecular glues. Plus new methods for mass spec tagging, viral inhibitors, and more.